Exposure‐Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis‐Associated Pain

• Autori principali: Ahmed Abbas Suleiman (Autore), Ahmed Nader (Autore), Insa Winzenborg (Autore), Denise Beck (Autore), Akshanth R. Polepally (Autore), Juki Ng (Autore), Peter Noertersheuser (Autore), Nael M. Mostafa (Autore)
• Natura: Libro
• Pubblicazione: Wiley, 2020-11-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Elagolix is a novel oral gonadotropin releasing hormone receptor antagonist, that can suppress estradiol in a dose‐dependent manner. It is indicated for management of moderate‐to‐severe pain associated with endometriosis. A population exposure‐response model describing the relationship between elago...